Syntekabio said Monday that it has appointed Choi Joon-hyuk, the former CEO of Target Health, to lead its U.S. operations.

Choi, who majored in electrical and computer engineering at Rutgers State University in New Jersey, has over 20 years of experience in various fields at Target Health, including clinical trial software development, quality assurance, and customer management.

He has extensive experience in U.S. Food and Drug Administration (FDA)’s drug and medical device approvals, clinical trial management, and business development. Most recently, he served as CEO of Target Health, leading business development, clinical trial management, and data management system development.

Syntekabio said Choi is the right person to understand AI drug discovery, clinical trials, sales, and marketing. He expects his appointment to contribute to strengthening strategic partnerships and increasing sales in the U.S. market.

“I will promote Syntekabio's AI drug platform with strategies tailored to the U.S. bio market,” Choi said.

Syntekabio CEO Jung Jong-sun said, “Mr. Choi's appointment will strengthen the company's competitiveness by equipping us with the ability to respond to customers' diverse needs throughout the entire drug development cycle. We expect him to play an important role in creating results in the U.S. and global markets.”